U081 Toxic Erythema of Chemotherapy: Comprehensive Approach to Diagnosis and Management
DESCRIPTION
This session will focus on a comprehensive approach to the diagnosis and management of toxic erythema of chemotherapy spectrum-related disorders. The session will focus on recognition, classification, and treatment of these toxicities as well as emerging treatments for hand foot syndrome, neutrophilic eccrine hidradenitis, and flexural and intertriginous eruptions.
LEARNING OBJECTIVES
Differentiate and recognize the clinical and histologic features of toxic erythema of chemotherapy spectrum disorders.
Choose appropriate therapies for each of the subsets of toxic erythema of chemotherapy, as well as formulate a comprehensive plan that includes recommendations regarding whether to continue or hold the implicated chemotherapeutic agent and implementation of detailed prophylactic measures to reduce the incidence of these toxicities.
Recognize emerging therapies for the treatment of toxic erythema of chemotherapy such as high dose oral vitamin D.
SCHEDULE
4:30 PM
Introduction and Clinical Presentation
Christopher Iriarte, MD, FAAD
4:45 PM
Histopathology & Differentiating Mimics
Cuong Nguyen, MD, FAAD
5:00 PM
Prophylaxis & Treatment
Jennifer N. Choi, MD, FAAD
5:20 PM
Updates/ Advances in TEC
DIRECTOR
Christopher Iriarte, MD, FAAD
SPEAKERS
Jennifer N. Choi, MD, FAAD
Cuong Nguyen, MD, FAAD
DISCLOSURES
Jennifer N. Choi, MD, FAAD
CeraVe/Valeante – Independent Contractor(Fees); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); PraHealth Sciences – Advisory Board(Fees); Pyxis Oncology – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);
Christopher Iriarte, MD, FAAD
No financial relationships exist with ineligible companies.
Cuong Nguyen, MD, FAAD
No financial relationships exist with ineligible companies.